Evidence map›Paper›PMID 31372241›Full record

ArticleCell death discovery2019

CircRNA_101505 sensitizes hepatocellular carcinoma cells to cisplatin by sponging miR-103 and promotes oxidored-nitro domain-containing protein 1 expression.

Yanwei Luo, Yunfeng Fu, Rong Huang, Meng Gao, Fengxia Liu, Rong Gui, Xinmin Nie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. NCellular & molecular biology letters · 2024
    Article
  5. Role of Epigenetics for the Efficacy of Cisplatin.International journal of molecular sciences · 2024
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Emerging roles of circular RNAs in liver cancer.JHEP reports : innovation in hepatology · 2022
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yanwei LuoDepartment of Blood Transfusion, the Third Xiangya Hospital of Central South University, Tongzipo Road 138, 410013 Changsha, China.
Yunfeng FuDepartment of Blood Transfusion, the Third Xiangya Hospital of Central South University, Tongzipo Road 138, 410013 Changsha, China.
Rong HuangDepartment of Blood Transfusion, the Third Xiangya Hospital of Central South University, Tongzipo Road 138, 410013 Changsha, China.
Meng GaoDepartment of Blood Transfusion, the Third Xiangya Hospital of Central South University, Tongzipo Road 138, 410013 Changsha, China.
Fengxia LiuDepartment of Blood Transfusion, the Third Xiangya Hospital of Central South University, Tongzipo Road 138, 410013 Changsha, China.
Rong GuiDepartment of Blood Transfusion, the Third Xiangya Hospital of Central South University, Tongzipo Road 138, 410013 Changsha, China.
Xinmin NieDepartment of Blood Transfusion, the Third Xiangya Hospital of Central South University, Tongzipo Road 138, 410013 Changsha, China.
Third Xiangya Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and a leading cause of cancer-related deaths worldwide. Emerging studies have shown that circular RNAs (circRNAs) are differentially expressed in HCC and play an important role in HCC pathogenesis and metastasis. However, the mechanism of circRNA in the chemoresistance of HCC remains unclear. In this study, we aimed to investigate the role of circRNA in cisplatin resistance of HCC. We identified a novel circRNA circRNA_101505 that was decreased in cisplatin-resistant HCC tissues and cell lines, and associated with a poor survival outcome. Gain-of-function investigations showed that overexpression of circRNA_101505 suppressed cancer cell growth in vivo and in vitro, and enhanced cisplatin toxicity in HCC cells. Mechanistic studies found that circRNA_101505 could sensitize HCC cells to cisplatin by sponging miR-103, and thereby promoting oxidored-nitro domain-containing protein 1 (NOR1) expression. In conclusion, the significant inhibitory effects indicate circRNA_101505 to be a potential therapeutic target for HCC treatment. Our findings provide significant evidence to further elucidate the therapeutic use of circRNA in HCC.

Indexed as

Cancer therapyTumour-suppressor proteins

Identifiers

PMID31372241
PMCPMC6662675
OpenAlexW2965944643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.